Premier Alternatives

Cresilon

New York, NY · Founded 2012 · Privately Held (backing)

Developer of hemostatic products designed to support the natural clotting and promote wound healing. Cresilon is based in New York, NY and was founded in 2012. Its last reported valuation was $340 million in Apr 2024. It has raised $160 million across 8 recorded rounds; the latest was a $29 million early-stage round in Apr 2026.

Last reported valuation
$340.0M
Oct 2026
Priced at
—
Total raised
$159.5M
Last round
Early Stage VC
Apr 2026

Cresilon key facts

as of Oct 2026
  • Developer of hemostatic products designed to support the natural clotting and promote wound healing.
  • Cresilon is valued at approximately $340.0M as of Oct 2026 (last reported valuation).
  • It has raised $159.5M across 8 recorded rounds; the latest was Early Stage VC ($29.0M) in Apr 2026.
  • Notable investors include Dorm Room Fund, First Round Capital, Catalio Capital Management, NYU Summer Launchpad, Hammerstone Capital — 20 tracked in total.
  • Cresilon has filed 8 Form Ds with the SEC since 2018, most recently Jun 2026 ($29.0M sold to 217 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$340.0M

Cresilon's last reported valuation, Apr 2024. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Cresilon with a free account
  • ·The complete investor list: 20 names
  • ·Watch Cresilon: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Cresilon funding rounds

8 rounds
Apr 2026Early Stage VC$29.0MSEC filing▮
Nov 2025Early Stage VC$6.7MSEC filing▮
Apr 2025Early Stage VC$17.2MSEC filing▮
Apr 2024Early Stage VC$25.0MSEC filing▮
Aug 2023Early Stage VC$17.2MSEC filing▮
Full funding history →

Cresilon valuation

Cresilon's last reported valuation was $340 million in Apr 2024. No priced round, secondary trade or fund mark has surfaced since.

How much has Cresilon raised?

Cresilon has raised $160 million across 8 recorded rounds since 2017. The largest was a $6.7 million early-stage round in Nov 2025; the most recent was a $29 million early-stage round in Apr 2026.

Cresilon has filed 8 Form Ds with the SEC since 2018, most recently in Jun 2026 ($29 million sold to 217 investors).

Cresilon investors

20 investors are on record for Cresilon, including Dorm Room Fund, First Round Capital, Catalio Capital Management and NYU Summer Launchpad. The early-stage round in Apr 2026 drew 217 investors.

About Cresilon

Developer of hemostatic products designed to support the natural clotting and promote wound healing. The company's products are plant-based polymers that rapidly adhere to the wound site and stop bleeding by creating a mechanical barrier, enabling medical practitioners to control external traumatic bleeding, improve wound care, and advance medical treatment.

Sector
Healthcare
HQ
New York, NY, United States
Founded
2012
Employees
88
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.